MarketCap
Facebook
X
Telegram
Aeterna Zentaris Market Cap | AEZS
As of October 06, 2026 Aeterna Zentaris has a market cap of $ 314 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Aeterna Zentaris
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 14.8 M | 3.66 M | 5.02 M | 41.4 M | 28.3 M | 18.7 M | 63 M | 32.3 M | 26.9 M | 3.99 B | 31.3 M | 38.6 M | 59.9 M | 158 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.99 B | 3.66 M | 322 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Puma Biotechnology
PBYI
|
378 M | $ 9.67 | 1.68 % | $ 484 M |  USA |
 |
Processa Pharmaceuticals
PCSA
|
4.14 M | $ 1.49 | 0.62 % | $ 1.95 M | USA |
 |
Vaxcyte
PCVX
|
8.38 B | $ 73.82 | 30.7 % | $ 10 B | USA |
 |
PDS Biotechnology Corporation
PDSB
|
25 M | $ 1.2 | 60.32 % | $ 55.7 M | USA |
 |
Pfizer
PFE
|
155 B | $ 27.41 | 0.02 % | $ 156 B | USA |
 |
Precigen
PGEN
|
970 M | $ 7.74 | 4.02 % | $ 2.42 B | USA |
 |
Pharming Group N.V.
PHAR
|
11.8 B | $ 9.8 | 0.51 % | $ 6.75 B |  Niderland |
 |
Phathom Pharmaceuticals
PHAT
|
986 M | $ 6.7 | 1.77 % | $ 489 M | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
7.06 M | $ 0.99 | 0.6 % | $ 5.92 M | USA |
 |
Pliant Therapeutics
PLRX
|
81.6 M | $ 1.03 | 0.48 % | $ 63.2 M | USA |
 |
Protalix BioTherapeutics
PLX
|
174 M | $ 2.71 | 0.37 % | $ 213 M |  Israel |
 |
PMV Pharmaceuticals
PMVP
|
85.6 M | $ 1.78 | 2.29 % | $ 93.5 M | USA |
 |
Praxis Precision Medicines
PRAX
|
7.31 B | $ 283.56 | 3.0 % | $ 6.38 B | USA |
 |
PainReform Ltd.
PRFX
|
1.72 M | $ 0.88 | 0.04 % | $ 570 K | Israel |
 |
Prelude Therapeutics Incorporated
PRLD
|
277 M | $ 3.77 | 2.72 % | $ 290 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
162 M | $ 1.67 | 2.14 % | $ 176 M | Niderland |
 |
Prothena Corporation plc
PRTA
|
251 M | $ 8.27 | 0.35 % | $ 445 M | USA |
 |
PTC Therapeutics
PTCT
|
5.56 B | $ 63.65 | 0.3 % | $ 5.06 B | USA |
 |
Protagonist Therapeutics
PTGX
|
5.53 B | $ 140.63 | 0.41 % | $ 8.94 B | USA |
 |
Pulmatrix
PULM
|
5.08 B | $ 1.48 | 0.64 % | $ 5.41 B | USA |
 |
PolyPid Ltd.
PYPD
|
67.7 M | $ 5.2 | 0.19 % | $ 85 M | Israel |
 |
Repare Therapeutics
RPTX
|
50 M | - | - | $ 112 M |  Canada |
 |
uniQure N.V.
QURE
|
626 M | $ 22.8 | 0.39 % | $ 1.31 B | Niderland |
 |
Rocket Pharmaceuticals
RCKT
|
308 M | $ 2.61 | 1.95 % | $ 290 M | USA |
 |
Arcus Biosciences
RCUS
|
2.17 B | $ 24.74 | 1.23 % | $ 2.66 B | USA |
 |
Regeneron Pharmaceuticals
REGN
|
81.3 B | $ 726.47 | 0.05 % | $ 76 B | USA |
 |
Replimune Group
REPL
|
1.04 B | $ 13.15 | 0.61 % | $ 1.22 B | USA |
 |
Rafael Holdings
RFL
|
39.4 M | $ 1.47 | 0.65 % | $ 43.3 M | USA |
 |
REGENXBIO
RGNX
|
444 M | $ 7.76 | 4.44 % | $ 400 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
598 M | $ 47.79 | 1.36 % | $ 860 M | USA |
 |
Relay Therapeutics
RLAY
|
546 M | $ 19.39 | 2.27 % | $ 3.33 B | USA |
 |
Avidity Biosciences
RNA
|
10 B | $ 7.97 | 1.66 % | $ 1.1 B | USA |
 |
Royalty Pharma plc
RPRX
|
18.9 B | $ 56.66 | 0.36 % | $ 24.4 B | USA |
 |
Revolution Medicines
RVMD
|
19.6 B | $ 207.68 | 0.5 % | $ 39.5 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
6.34 B | $ 92.45 | 0.24 % | $ 6.01 B | USA |
|
Rezolute
RZLT
|
409 M | $ 4.33 | 7.98 % | $ 450 M | USA |
 |
Sana Biotechnology
SANA
|
995 M | $ 2.88 | 1.21 % | $ 729 M | USA |
 |
Seer
SEER
|
123 M | $ 2.33 | 3.56 % | $ 129 M | USA |
 |
SIGA Technologies
SIGA
|
404 M | $ 3.48 | 2.96 % | $ 249 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
203 M | $ 78.95 | 9.65 % | $ 220 M | Israel |
|
Silence Therapeutics plc
SLN
|
812 M | $ 10.14 | 0.78 % | $ 1.44 B |  Britain |
 |
SELLAS Life Sciences Group
SLS
|
567 M | $ 11.63 | 3.62 % | $ 1.27 B | USA |
 |
Summit Therapeutics
SMMT
|
12 B | $ 17.27 | 3.07 % | $ 12.9 B | Britain |
 |
Syndax Pharmaceuticals
SNDX
|
1.73 B | $ 17.83 | 1.31 % | $ 1.54 B | USA |
 |
Soligenix
SNGX
|
6.12 M | $ 0.36 | 0.6 % | $ 1.87 M | USA |
 |
Sanofi
SNY
|
59.3 B | $ 39.51 | 1.19 % | $ 48.2 B |  France |
 |
Spruce Biosciences
SPRB
|
47.6 M | $ 45.42 | 2.1 % | $ 34.8 M | USA |
 |
Spero Therapeutics
SPRO
|
133 M | $ 1.16 | 4.13 % | $ 65 M | USA |
 |
Sarepta Therapeutics
SRPT
|
1.64 B | $ 17.49 | 0.7 % | $ 1.75 B | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
5.09 B | $ 43.4 | 1.41 % | $ 4.98 B | USA |